IP Library › Granted Patent US 12,521,436
Granted Patent B2
US 12,521,436 · App. 17/802,978 · Granted Jan 13, 2026

Method and kit for treating skin infections

Inventors: Sakari Nikinmaa (Espoo, FI); Juha Rantala (Espoo, FI); Tommi Pätilä (Espoo, FI)
Assignee: Koite Health Oy
A61K41/0057A61N5/062A61N5/0624A61N2005/0651A61N2005/0662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,436
App. No.
17/802,978
Granted
Jan 13, 2026
Kind
B2
Abstract

Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus . The method comprises the steps of applying a photosensitizer to at least a part of the skin affected by the infection, and subjecting said part of the skin to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level; and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 10:1 to 2:1. By the method efficient treatment of Staphylococcus aureus infections can be achieved without the administration of topical antibiotics.

Claims (32)

1 . A method for topical treatment of an infection caused by Staphylococcus aureus on a mammal, comprising the steps of:

applying a photosensitizer to at least a part of a biological surface affected by the infection, and

subjecting said part of the biological surface with the applied photosensitizer to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 5:0.8 to 3.5:0.9.

2 . The method according to claim 1 , wherein:

non-coherent radiant light energy is generated at two different energy levels: the first and the second energy level;

from the non-coherent radiant light energy there is provided first light having a wavelength corresponding to the majority energy of the first energy level, and second light having a wavelength corresponding to the majority energy of the second energy level; and

the first and second light are simultaneously directed against the biological surface.

3 . The method according to claim 2 , wherein the first light and the second light consist of the first light having the first photons with a majority energy between 2.8 eV and 3.5 eV; and the second light having the second photons with a majority energy between 1.24 eV and 1.65 eV.

4 . The method according to claim 1 , wherein the first photons and the second photons are emitted using feed-in voltage or current that is alternated or pulsed at 1 Hz to 1 GHz frequency independently from each other.

5 . The method according to claim 1 , comprising using an optoelectronic device having a plurality of semiconductor chips that are connected in series or in parallel, the chips exhibiting emission energy that can be varied in the range of 2.48 eV and 1.24 eV and in the range of 3.5 eV and 2.8 eV, respectively.

6 . The method according to claim 1 , wherein the photosensitizer is selected from a natural compound, a synthetic photosensitizer, or combinations thereof,

wherein the natural compound is selected from the group consisting of hypericin, curcumin, phenalenone derivatives, cercosporin, psoralen, xanthotoxin, angelicin, alpha-terthienyl, phenylheptatriyne, THC, cannabidiol (CBD), and combinations thereof, and

wherein the synthetic photosensitizer is selected from the group consisting of RB (Rose Bengal), porphyrin derivatives, curcumin derivatives, methylene blue, indocyanine green, erythrosine, phenalenone derivatives, fullerene derivatives, xanthene derivatives, and combinations thereof.

7 . The method according to claim 1 , wherein light energy is directed towards the biological surface at a first wavelength from 400 to 430 nm at a dosage of 1 to 750 J/cm 2 with a power density of from about 10 to about 2500 mW/cm 2 for a period of time from 0.5 s to 120 min, and at a second wavelength from 780 to 830 nm at a dosage of 1 to 750 J/cm 2 with a power density of from about 10 to about 2500 mW/cm 2 for a period of time from 0.5 s to 120 min.

8 . The method according to claim 1 , wherein the first and second photons are produced by one or several light-emitting diodes.

9 . The method according to claim 1 , wherein the photosensitizer is Indocyanine Green.

10 . The method according to claim 1 , comprising treating superficial skin infections caused by Staphylococcus aureus or comprising treating infections caused by Staphylococcus aureus on and in organs and organ tissues, superficial skin, skin tissues, body fluids, prosthetics and parts thereof and artificial tissues.

11 . The method according to claim 1 , comprising carrying out the topical treatment for a duration of 0.5 s to 120 min, 1 to 5 times a day, for 1 to 14 days.

12 . The method according to claim 1 , comprising carrying out the topical treatment for a duration of 0.5 s to 120 min, 2 to 50 times during 1 to 14 days.

13 . A kit for topical treatment of an infection caused by Staphylococcus aureus on a mammal, comprising:

an optoelectronic device configured for simultaneously emitting a first light comprising first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level and a second light comprising second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 5:0.8 to 3.5:0.9, and

at least one photosensitizer which can be activated by either or both of the first photons and the second photons.

14 . The kit according to claim 13 , wherein the first and said second light amounts to at least 80% of all light emitted from the optoelectronic device.

15 . The kit according to claim 13 , wherein the optoelectric device is configured to emit two wavelengths simultaneously or at a time interval of 0.001 to 1000 ms, together with the photosensitizer for topical treatment of a skin infection on the skin of a mammal caused by Staphylococcus aureus.

16 . The kit according to claim 13 , wherein the photosensitizer is selected from a natural compound, a synthetic photosensitizer, or combinations thereof

wherein the natural compound is selected from the group consisting of hypericin, curcumin, phenalenone derivatives, cercosporin, psoralen, xanthotoxin, angelicin, alpha-terthienyl, phenylheptatriyne, THC, cannabidiol (CBD), and combinations thereof, and

wherein the synthetic photosensitizer is selected from the group consisting of RB (Rose Bengal), porphyrin derivatives, curcumin derivatives, methylene blue, indocyanine green, erythrosine, phenalenone derivatives, fullerene derivatives, xanthene derivatives, resveratrol, berry extracts, polyphenolic compounds, anthocyanin compounds and combinations thereof.

17 . The kit according to claim 13 , wherein the optoelectronic device is configured to emit non-coherent light, comprising:

the first photons at a first wavelength from 400 to 430 nm, at a dosage of 1 to 750 J/cm 2 , and a power density of from about 10 to about 2500 mW/cm 2 for a period of time from 0.5 s to 120 min, and

the second photons at a second wavelength from 780 to 830 nm, at a dosage of 1 to 750 J/cm 2 , and with a power density of from about 10 to about 2500 mW/cm 2 for a period of time from 0.5 s to 120 min.

18 . The kit according to claim 13 , wherein the optoelectronic device is configured to emit non-coherent light.

19 . The kit according to claim 13 , wherein the optoelectric device comprises light-emitting diode(s) as a light source.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: NIKINMAA, SAKARI; RANTALA, JUHA; PÄTILÄ, TOMMI
To: KOITE HEALTH OY
Reel/Frame 064252/0753 →
Priority Claims (1)
FI 20205206 · Feb 27, 2020 · national
Continuity (1)
Related Publication 20230149545A1 · May 18, 2023
References Cited (26)
US 12161719B2 · Pätilä · 2024 [cited by examiner]
US 12263349B2 · Nikinmaa · 2025 [cited by examiner]
US 20020165594A1 · Biel · 2002 [cited by applicant]
US 20040193235A1 · Altshuler · 2004 [cited by examiner]
US 20180311507A1 · Barolet · 2018 [cited by applicant]
US 20200054893A1 · Yoon et al. · 2020 [cited by applicant]
US 20210030874A1 · Pätilä · 2021 [cited by examiner]
CN 1771073A · 2006 [cited by applicant]
WO WO2014131115A1 · 2014 [cited by applicant]
WO WO2019092215A1 · 2019 [cited by applicant]
WO WO2020036436A1 · 2020 [cited by applicant]
WO WO2020084199A1 · 2020 [cited by applicant]
WO WO2020193870A1 · 2020 [cited by applicant]
WO WO2021023915A1 · 2021 [cited by applicant]
Kaya, Göksel Şimşek et al. (“The use of 808-nm light therapy to treat experimental chronic osteomyelitis induced in rats by methicillin-resistant [cited by examiner]
Ghorbani et al: Photosensitizers in antibacterial photodynamic therapy: An overview. Laser Therapy, Dec. 31, 2018, pp. 293-302. [cited by applicant]
Bumah et al: Wavelength and Bacterial Density Influence the Bactericidal Effect of Blue Light on Methicillin-Resistant [cited by applicant]
Gueffey et al: Effects of Combined 405-nm and 880-nm Light on [cited by applicant]
Nielsen et al: Choice of Optimal Wavelength for PDT: The Significance of Oxygen Depletion. Photochemistry and Photobiology, Jan. 1, 2005, vol. 81, No. 5, p. 1190. [cited by applicant]
Nikinmaa et al: Dual-light photodynamic therapy administered daily provides a sustained antibacterial effect on biofilm and prevents [cited by applicant]
Omar et al: Lethal photosensitization of wound-associated microbes using indocyanine green and near-infrared light. BMC Microbiology, Jul. 1, 2008, vol. 8, No. 111. [cited by applicant]
Topaloglu et al: Antimicrobial Photodynamic Therapy of Resistant Bacterial Strains by Indocyanine Green and 809-nm Diode Laser. Photomedicine Ano Laser Surgery, Apr. 1, 2013, vol. 31, No. 4, pp. 155-162. [cited by applicant]
Wong et al: Photodynamic inactivation of methicillin-resistant [cited by applicant]
Bumah et al: Optimization of the Antimicrobial Effect of Blue Light on Methicillin-Resistant [cited by applicant]
Giannelli et al: Appropriate laser wavelengths for photodynamic therapy with methylene blue. Lasers in Medical Science, Jun. 30, 2018, vol. 33, No. 8, pp. 1837-1838. [cited by applicant]
Tao: In Vitro Study on the Effect of Curcumin-Mediated Photodynamic Therapy against Methicillin-Resistant [cited by applicant]